STIM vs. DCTH, CLPT, ZIMV, SMLR, NPCE, NYXH, TCMD, NNOX, LUNG, and CVRX
Should you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include Delcath Systems (DCTH), ClearPoint Neuro (CLPT), ZimVie (ZIMV), Semler Scientific (SMLR), NeuroPace (NPCE), Nyxoah (NYXH), Tactile Systems Technology (TCMD), Nano-X Imaging (NNOX), Pulmonx (LUNG), and CVRx (CVRX). These companies are all part of the "medical equipment" industry.
Neuronetics vs.
Neuronetics (NASDAQ:STIM) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking.
Neuronetics currently has a consensus target price of $5.50, suggesting a potential upside of 21.15%. Delcath Systems has a consensus target price of $22.75, suggesting a potential upside of 92.80%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts plainly believe Delcath Systems is more favorable than Neuronetics.
In the previous week, Delcath Systems had 2 more articles in the media than Neuronetics. MarketBeat recorded 17 mentions for Delcath Systems and 15 mentions for Neuronetics. Delcath Systems' average media sentiment score of 0.31 beat Neuronetics' score of 0.12 indicating that Delcath Systems is being referred to more favorably in the news media.
Neuronetics has higher revenue and earnings than Delcath Systems. Delcath Systems is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.
Neuronetics has a net margin of -50.09% compared to Delcath Systems' net margin of -150.70%. Neuronetics' return on equity of -141.24% beat Delcath Systems' return on equity.
Neuronetics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.
Neuronetics received 96 more outperform votes than Delcath Systems when rated by MarketBeat users. Likewise, 68.62% of users gave Neuronetics an outperform vote while only 27.50% of users gave Delcath Systems an outperform vote.
53.6% of Neuronetics shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 9.8% of Neuronetics shares are held by company insiders. Comparatively, 17.9% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Neuronetics and Delcath Systems tied by winning 9 of the 18 factors compared between the two stocks.
Get Neuronetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neuronetics Competitors List
Related Companies and Tools
This page (NASDAQ:STIM) was last updated on 3/11/2025 by MarketBeat.com Staff
